SelectQuote (SLQT)SelectQuote IncBATS:SLQTKalaGhaziSelectQuote (SLQT) Navigates Growth and Headwinds with 12% Revenue Increase and Strategic $415M Debt Refinancing SelectQuote Inc. (NYSE: SLQT), a technology-enabled direct-to-consumer platform specializing in insurance distribution and healthcare services, delivered a mixed but operationally significant performance in its fiscal second quarter of 2026. The company reported consolidated revenue of $537 million for the quarter ended December 31, 2025, representing a 12% year-over-year increase driven by strength in its Senior segment during the Annual Enrollment Period (AEP) and continued robust growth in its Healthcare Services division . However, the positive top-line results were accompanied by a downward revision to full-year guidance and temporary margin pressure in key segments, leading to a volatile market reaction. The company's stock fell approximately 28.6% following the announcement, reflecting investor focus on near-term profitability challenges rather than the underlying revenue momentum and strategic balance sheet improvements . Segment Performance: Diversified Growth with Contrasting Profitability Senior Segment: The core Senior segment, which focuses on Medicare Advantage and Medicare Supplement plans, delivered modest revenue growth of 2% year-over-year to $262 million . More notably, the segment maintained near-record profitability with Adjusted EBITDA of $102 million and an impressive 39% margin . This performance was achieved despite another highly disruptive AEP characterized by approximately 7% carrier plan terminations, significantly higher than historical levels of less than 1%. SelectQuote's high-touch, proactive outreach model demonstrated its value, achieving a 33% recapture rate for customers impacted by terminated plans, compared to industry averages . Approved Medicare Advantage policies grew 4% to 257,000, while agent productivity improved and marketing cost per approved policy remained disciplined at $326 . Healthcare Services: The Healthcare Services segment, anchored by the SelectRx pharmacy platform, continued its rapid expansion with revenue surging 26% year-over-year to $231 million . SelectRx membership grew 17% to approximately 113,000 members, demonstrating strong adoption of the company's patient-centered pharmacy model . However, segment profitability faced significant pressure, with Adjusted EBITDA declining to $0.8 million from $2 million in the prior-year quarter, reflecting "previously discussed PBM reimbursement rate pressure" . The company highlighted the clinical impact of SelectRx, citing an observed ~20% reduction in inpatient hospital days among beneficiaries through comprehensive medication management practices . Life Segment: The Life segment delivered steady performance with revenue increasing 9% year-over-year to $44 million, driven by 24% growth in Final Expense premiums . Adjusted EBITDA for the segment was $5.6 million . Strategic Financing: The $415 Million Credit Facility Transformation A pivotal development during the quarter was the successful completion of a comprehensive debt refinancing that fundamentally strengthens SelectQuote's capital structure. On January 12, 2026, the company announced the closing of a new $415 million senior secured credit facility . The facility is comprised of two key components: A $325 million term loan provided by Pathlight Capital LP, serving as administrative agent An enhanced $90 million revolving credit facility with UMB Bank, representing a 25% increase in peak-season liquidity compared to the prior facility limit of $72 million This refinancing delivers several critical benefits : Significantly Extended Maturities: The new facility extends term debt maturity to January 2031, eliminating the previous 2026 and 2027 repayment obligations. This provides multi-year visibility and removes near-term refinancing risk. Improved Cost of Capital: The transaction provides a slightly improved cost of capital with future interest rate step-downs totaling up to 100 basis points, tied to continued operational and financial performance. Enhanced Operational Flexibility: Lower principal amortization and greater investment flexibility allow management to allocate capital toward growth initiatives rather than debt service. Balance Sheet Validation: The participation of Pathlight Capital, a specialized private credit manager, and the continued partnership with UMB Bank represent strong endorsements of SelectQuote's business model and cash flow generation potential. CEO Tim Danker emphasized the strategic importance of the transaction: "This new financing agreement positions us well to continue to invest and grow our industry-leading senior health insurance and healthcare services businesses" . CFO Ryan Clement added that the facility provides "a strong foundation for future growth" and represents "clear validation of our business model and the confidence our lending partners have in SelectQuote's cash flow generation capabilities" . Revised Guidance: Navigating External Headwinds Despite the strong quarterly performance and capital structure improvements, SelectQuote revised its full-year fiscal 2026 guidance downward to reflect two discrete external headwinds totaling approximately $40 million : A $20 million impact resulting from a national carrier's marketing budget cuts affecting the Senior segment A $20 million headwind from changes in pharmacy benefit manager (PBM) reimbursement rates affecting Healthcare Services margins The updated guidance reflects : Consolidated Revenue: $1.61 billion to $1.71 billion (revised from $1.65-1.75 billion) Adjusted EBITDA: $90 million to $100 million (revised from $120-150 million) Operating Cash Flow: $25 million to $35 million for fiscal 2026, a significant improvement from negative $12 million in fiscal 2025 Management emphasized that these revisions reflect external factors rather than internal performance deterioration. Importantly, the company announced a new multi-year agreement with a major PBM partner signed in January 2026, which will provide greater stability and predictability in reimbursement rates moving forward, mitigating one of the key headwinds . Competitive Positioning and Strategic Outlook CEO Tim Danker expressed confidence in SelectQuote's ability to navigate market volatility, citing the company's scale—managing over 100,000 complex members—as a significant negotiating strength . The company's diversified model, spanning insurance distribution and healthcare services, provides multiple avenues for growth while spreading risk across complementary businesses. The Senior segment's ability to maintain near-record 39% EBITDA margins despite significant carrier disruption demonstrates the resilience of SelectQuote's direct-to-consumer model and the value of its high-touch customer service approach . Meanwhile, Healthcare Services continues to scale rapidly, with management targeting an annualized Adjusted EBITDA exit rate of $40-50 million . Management has emphasized a renewed focus on cash flow generation, forecasting Cash EBITDA of $60-70 million for fiscal 2026, representing approximately 20% year-over-year growth at the midpoint . This disciplined approach to profitability, combined with the strengthened balance sheet, positions SelectQuote to execute on its strategic priorities. Upcoming Investor Engagement SelectQuote management will continue to communicate its strategic vision and operational progress to the investment community. On March 5, 2026, CEO Tim Danker and CFO Ryan Clement will participate in Mizuho's 2026 Virtual Healthcare Technology Conference, where they will be available for one-on-one and small group investor meetings . Conclusion: A Strengthened Foundation for Long-Term Value SelectQuote's fiscal second-quarter results encapsulate the complexity of the company's turnaround story: robust revenue growth and exceptional segment profitability juxtaposed against near-term external headwinds and revised guidance. The successful $415 million refinancing represents a pivotal achievement, eliminating near-term debt maturities, enhancing liquidity, and providing a stable capital foundation for future investment. For investors willing to look through the temporary margin pressures in Healthcare Services, the underlying thesis remains compelling. SelectQuote has demonstrated its ability to navigate a highly disrupted Medicare market while maintaining best-in-class margins. Its SelectRx pharmacy platform continues to scale rapidly, addressing critical healthcare needs for seniors while creating a durable, recurring revenue stream. With a strengthened balance sheet, improving cash flow trajectory, and a diversified business model spanning insurance and healthcare services, SelectQuote appears well-positioned to deliver long-term shareholder value as it executes through the current transitional period. The company's participation in upcoming investor conferences will provide further opportunity for management to articulate its vision and demonstrate progress against its strategic priorities.